Ocugen, Inc. Q3 2026 Financial Results and Business Highlights - OCUGEN INC

Financial Performance:

• Total cash, cash equivalents, restricted cash, and short-term investments stood at $84.6 million as of September 30, 2026.
• Cash runway is projected to extend into 2028, funding two of three late-stage programs through anticipated BLA filings.
• Total operating expenses for the quarter ended September 30, 2026, were $19.7 million ($12.5 million R&D, $7.2 million G&A), up slightly from $19.4 million in the prior year period.
• Net loss per share was $0.01 for the quarter ended September 30, 2026, compared to $0.07 in the same period last year.
• For the nine months ended September 30, 2026, total operating expenses were $57 million, with a net loss per share of $0.14, compared to $1.17 in the prior year period.

Guidance and Future Outlook:

• Management remains on track to file three Biologics License Applications (BLAs) by 2028.
• Top-line data for OCU-400 (Retinitis Pigmentosa) is expected in Q1 2027, followed by a planned BLA submission.
• Top-line data for OCU-410-ST (Stargardt Disease) is anticipated in Q2 2027.
• The Phase III "Armada 3" trial for OCU-410 (Geographic Atrophy) plans to complete enrollment in 2027, with a target BLA filing in 2028.
• Long-term goal is to advance three late-stage gene therapy programs to approval and commercialization globally.

Business Segments and Product Lines:

• OCU-400 (Retinitis Pigmentosa): Completed enrollment of 140 patients in the Phase III "Limelight" trial; process performance qualification batches are complete. Secured an exclusive license for Middle East and North Africa (MENA) with Roots Pharmaceutical, entitling Ocugen to up to $4M upfront/development milestones, $255M in sales milestones, and a 22% royalty.
• OCU-410-ST (Stargardt Disease): Advanced in Phase II/III "Guardian" trial; data readout expected Q2 2027. No approved therapies currently exist for this pediatric onset disorder.
• OCU-410 (Geographic Atrophy): First patient dosed in the Phase III "Armada 3" global trial (237 subjects). Targets a one-time treatment for a condition currently requiring monthly injections, addressing multiple disease pathways.
• OCU-400 (Bahamas Access): Received provisional approval and priority designation in the Bahamas under LARTA; full approval expected by year-end to treat patients, potentially generating early commercial revenue.
• Commercial Strategy: Established European presence for pre-commercial activities; utilizing regional licensing partnerships to expand international reach without building local infrastructure.

Market and Competitive Landscape:

• OCU-410 (GA) addresses the largest commercial opportunity, offering a potential competitive advantage as a single-dose, multifactorial treatment versus current therapies requiring ongoing intraocular injections.
• OCU-400 targets Geographic Atrophy (GA), Retinitis Pigmentosa (RP), and Stargardt disease, positioning Ocugen as a multifactorial, gene-agnostic platform provider.
• The Bahamas LARTA pathway represents a novel global Expanded Access Program (EAP) model, distinct from typical clinical trials, allowing for commercial-like pricing structures.
• Management highlighted the platform's ability to restore balance across multiple gene networks, addressing underlying biology rather than single mutations.

Risks and Challenges:

• Regulatory timelines remain subject to FDA approval and potential delays in BLA submissions.
• Clinical trial outcomes depend on patient selection, disease progression rates (slowly progressive retinal diseases), and potential baseline heterogeneity.
• Commercialization risks include the execution of international licensing deals and the success of the Bahamas patient access model.
• Forward-looking statements involve inherent risks regarding clinical development, regulatory approval, and financial runway.

Management Commentary and Tone:

• Management expressed high confidence in the execution strategy and the strength of the clinical data supporting Phase III designs.
• The tone was focused and operational, emphasizing the transition from early-stage development to late-stage execution and commercialization readiness.
• CFO emphasized the efficiency of the burn rate and the adequacy of cash reserves to reach the next major catalysts (BLAs).
• Dr. Musunori reinforced the "gene-agnostic" platform value proposition and the strategic shift toward global partnerships.

Analyst Questions and Answers:

• Stargardt (OCU-410-ST) Interim Analysis: Clarified that the December Data Monitoring Committee (DMC) review was an adaptive design feature based on an early timepoint (8 months) and small cohort size. The DMC recommended continuing the study without modification; full 12-month data will be the primary analysis point.
• OCU-410 (GA) Trial Design: Confirmed "Armada 3" is a 1-year trial with no planned interim analysis; recruitment goal is completion in 2027.
• OCU-400 Powering: Management detailed a conservative statistical model showing 93.2% power even at a 20% responder rate. Phase I-II data showed a 71.4% projected responder rate on the LDNA scale versus 0% in controls.
• Bahamas Program: Confirmed global eligibility for the EAP; pricing will align with U.S./international commercial targets. Patient education will be handled by a local vendor, with marketing not directly conducted by Ocugen.
• Phase III RP Trial Timeline: Confirmed database lock and top-line results are on track for announcement by the end of Q1 2027 following enrollment completion in Q3 2026.

Other Key Points:

• Ocugen has three late-stage modifier gene therapy programs in Phase III, a unique milestone for the company.
• The company is leveraging the Bahamas LARTA act to potentially generate revenue and gather real-world data prior to US regulatory approval.
• OCU-410 (GA) is noted as the first pivotal gene therapy trial in geographic atrophy.
• The company maintains a 339.3 million share count as of September 30, 2026.
• Emphasis was placed on the durability of the single-injection approach compared to the chronic nature of current standard-of-care treatments for GA.